Roche warns that Trump's drug pricing orders may necessitate a reevaluation of its investments in the United States.

Swiss pharmaceutical company Roche said that if U.S. President Trump implements an executive order to cut prescription drug costs, the company will need to reconsider its planned investments in the United States. Roche had announced last month plans to invest $50 billion in the pharmaceutical and diagnostic fields in the U.S. over the next five years, creating over 12,000 job opportunities. Roche expects that the executive order will not have an impact on its business this year, but believes it will undermine the U.S. as a world leader in pharmaceuticals and healthcare ecosystems, stifle economic growth, and lead to unemployment.